1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Summary
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
Real-time Euronext Paris  -  11:37 2022-08-18 am EDT
9.906 EUR   -0.04%
01:41pValneva Initiates Rolling Submission of US FDA Biologics License Application for Chikungunya Vaccine
MT
12:01pValneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
GL
12:00pValneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Valneva Reiterates Timelines for Lyme Disease, Chikungunya Vaccine Candidates

06/24/2022 | 01:38am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
PFIZER, INC. -1.63% 48.46 Delayed Quote.-16.56%
VALNEVA SE -0.04% 9.906 Real-time Quote.-59.55%
All news about VALNEVA SE
01:41pValneva Initiates Rolling Submission of US FDA Biologics License Application for Chikun..
MT
12:01pValneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
GL
12:00pValneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
AQ
10:28aValneva's COVID-19 Vaccine Recommended for Use by World Health Organization
MT
09:45aWHO recommends Valneva's COVID vaccine
RE
09:20aWHO recommends Valneva's COVID vaccine
RE
05:38aValneva Says Pentagon Didn't Exercise 2nd Option Year of Supply Contract for Japanese E..
MT
03:14aVALNEVA : U.S. Dept of Defense ends Ixiaro vaccine supply deal
RE
01:22aValneva Says US Defense Department Waived Second-year Supply Option For Japanese Enceph..
MT
01:10aVALNEVA : U.S. Dept of Defense ends Ixiaro vaccine supply deal
RE
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Financials
Sales 2022 337 M 341 M 341 M
Net income 2022 9,30 M 9,43 M 9,43 M
Net cash 2022 290 M 294 M 294 M
P/E ratio 2022 124x
Yield 2022 -
Capitalization 1 162 M 1 177 M 1 177 M
EV / Sales 2022 2,59x
EV / Sales 2023 3,42x
Nbr of Employees 700
Free-Float 68,2%
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 9,91 €
Average target price 15,92 €
Spread / Average Target 60,6%
EPS Revisions
Managers and Directors
Thomas Lingelbach President & Chief Executive Officer
Franck Charles Marie Grimaud Director General & Chief Business Officer
Peter Buhler Chief Financial Officer
Frédéric Grimaud Chairman-Supervisory Board
Michael Möhlen Vice President-Technical Development
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE-59.55%1 181
MODERNA, INC.-37.79%61 810
IQVIA HOLDINGS INC.-14.72%44 878
LONZA GROUP AG-26.39%43 629
SEAGEN INC.10.47%31 500
ALNYLAM PHARMACEUTICALS, INC.31.58%26 782